## Douglas J Biedenbach

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8002462/publications.pdf

Version: 2024-02-01

18	858	13	18
papers	citations	h-index	g-index
19	19	19	1356
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Pathogen Prevalence and Antimicrobial Susceptibility Among Enterobacteriaceae Causing Hospital-associated Intra-abdominal Infections in Adults in the United States (2012–2013). Clinical Therapeutics, 2016, 38, 1510-1521.	2.5	19
2	Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam. Clinical Therapeutics, 2016, 38, 2098-2105.	2.5	21
3	In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012–2014. Diagnostic Microbiology and Infectious Disease, 2016, 86, 194-199.	1.8	20
4	In Vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance Study. Infectious Diseases and Therapy, 2016, 5, 139-153.	4.0	9
5	<i>In vitro</i> activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme. Journal of Antimicrobial Chemotherapy, 2016, 71, 162-169.	3.0	24
6	Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo- $\hat{l}^2$ -Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2016, 60, 1067-1078.	3.2	171
7	In vitro activity of tigecycline against molecularly characterised strains of Enterobacteriaceae isolated from phase 3 clinical trials and the Tigecycline Evaluation and Surveillance Trial (TEST). Journal of Global Antimicrobial Resistance, 2015, 3, 311-312.	2.2	O
8	Activity of ceftaroline and comparators against pathogens isolated from skin and soft tissue infections in Latin America – results of AWARE surveillance 2012. Brazilian Journal of Infectious Diseases, 2015, 19, 596-603.	0.6	10
9	In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011–2014. International Journal of Antimicrobial Agents, 2015, 46, 674-681.	2.5	22
10	<i>In Vitro</i> Activity of Aztreonam-Avibactam against a Global Collection of Gram-Negative Pathogens from 2012 and 2013. Antimicrobial Agents and Chemotherapy, 2015, 59, 4239-4248.	3.2	111
11	Trends in Susceptibility of Escherichia coli from Intra-Abdominal Infections to Ertapenem and Comparators in the United States According to Data from the SMART Program, 2009 to 2013. Antimicrobial Agents and Chemotherapy, 2015, 59, 3606-3610.	3.2	81
12	<i>In Vitro</i> Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program. Antimicrobial Agents and Chemotherapy, 2015, 59, 7873-7877.	3.2	14
13	<i>In Vitro</i> Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens. Antimicrobial Agents and Chemotherapy, 2015, 59, 6053-6063.	3.2	18
14	Antimicrobial susceptibility and extended-spectrum beta-lactamase rates in aerobic gram-negative bacteria causing intra-abdominal infections in Vietnam: report from the Study for Monitoring Antimicrobial Resistance Trends (SMART 2009–2011). Diagnostic Microbiology and Infectious Disease, 2014, 79, 463-467.	1.8	30
15	In vitro susceptibility of Gram-negative isolates from patients with urinary tract infections in Vietnam: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Journal of Global Antimicrobial Resistance, 2014, 2, 338-339.	2.2	2
16	A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals, 2013, 6, 1335-1346.	3.8	199
17	Characterization of fluoroquinolone-resistant β-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: Report from the SENTRY Antimicrobial Surveillance Program (1997–2004). Diagnostic Microbiology and Infectious Disease, 2006, 55, 119-127.	1.8	60
18	Fluoroquinolone-resistant Haemophilus influenzae: Frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America). Diagnostic Microbiology and Infectious Disease, 2000, 36, 255-259.	1.8	45